Michael T. Guskey
YOU?
Author Swipe
View article: 158 Open-label Study of Pimavanserin Patients with Comorbid Parkinson’s Disease and Depression
158 Open-label Study of Pimavanserin Patients with Comorbid Parkinson’s Disease and Depression Open
Study Objectives: Depression occurs in ~50% of Parkinson’s disease (PD) patients, increases in severity and duration as the disease progresses, and is associated with increased morbidity. Improvement of depression in PD patients is correla…
View article: Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications
Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive‐enhancing medications Open
Background : PD psychosis is often associated with cognitive impairment, including dementia, and involves dopaminergic, serotonergic, and cholinergic mechanisms. Objective : To evaluate the differential effect of the antipsychotic pimavans…